AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +65

AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap

📊 Technical Analysis: Both AbbVie and Baxter flashed a 'golden cross' signal, but AbbVie's is widening with rising averages while Baxter's sits atop a declining 200-day moving average.

💰 Dividend Status: AbbVie declared a $1.73 quarterly payout (2.8% yield) extending a 13-year increase streak, whereas Baxter slashed its dividend to $0.01 per share.

📉 Financial Performance: Baxter posted a -$900 million net income in FY2025 due to goodwill and intangible impairments, while AbbVie maintains a $432.5 billion market cap and 26.6% operating margin.

💊 Growth Drivers: AbbVie's Skyrizi grew 30.9% and Rinvoq rose 23.3% in Q1 2026, more than offsetting Humira's biosimilar erosion.

📈 Guidance Update: Following the Q1 report, AbbVie raised its full-year adjusted EPS guidance to a range of $14.08 to $14.28.

🎯 Price Targets: The consensus price target for AbbVie is $265.50 compared to a recent close of $244.78, while Baxter's target is below its current price.

🛑 Operational Risks: Baxter faces challenges including the Novum IQ LVP pump shipment hold, tariff pressure, and a reset following the Kidney Care sale.

📉 Stock History: AbbVie shares returned 27.8% over the past year, while Baxter shares are down 53.4% over the last decade.

👔 Leadership Change: Baxter appointed new CEO Andrew Hider in September 2025 to lead a turnaround and write a new operating model.

🏆 Portfolio Fit: The article concludes AbbVie is the definitive choice for retirees needing income, while Baxter remains only suitable for deep-value investors with no need for dividends.

Bullish Signals
  • AbbVie declared a $1.73 quarterly dividend with an ex-dividend date of July 15, 2026, extending a 13-year streak of annual increases.
  • Skyrizi revenue grew 30.9% to $4.48 billion and Rinvoq rose 23.3% to $2.12 billion in Q1 2026, offsetting Humira losses.
  • Management raised full-year adjusted EPS guidance to $14.08-$14.28 following strong Q1 results.
  • AbbVie maintains a low beta of 0.283, indicating roughly one-quarter of the market's volatility.
  • The stock has returned 27.8% over the past year and 478.9% over 10 years including reinvested momentum.
  • Consensus price target of $265.50 is significantly higher than the current trading price of $244.78.
Risk Factors
  • Baxter posted a -$900 million net income in FY2025 after recording $485 million in goodwill impairments and $290 million in intangible impairments.
  • Baxter's quarterly dividend was slashed to $0.01, effectively eliminating the payout for income-focused investors.
  • Baxter carries negative book value due to buybacks and Allergan-era leverage issues.
  • Baxter faces operational overhangs including a hold on Novum IQ LVP pump shipments and tariff pressure.
  • Analyst consensus price target for Baxter is $21.71, which is less than the current stock price.
Full Analysis
The article compares AbbVie (ABBV) and Baxter International (BAX), concluding that while both recently displayed a 'golden cross' technical signal, only AbbVie represents a viable option for income-focused retirement portfolios. AbbVie's signal is described as widening with rising moving averages, whereas Baxter's is characterized as razor-thin and sitting atop a declining 200-day moving average. Fundamentally, the divergence between the two companies is stark. AbbVie declared a quarterly dividend of $1.73, maintaining a 13-year streak of increases and offering a yield near 2.8% at its current price. In contrast, Baxter effectively eliminated its dividend to just $0.01 per share following poor financial results in FY2025, which included a net loss of $900 million. AbbVie's growth is driven by its immunology franchise, where Skyrizi and Rinvoq revenues grew 31% and 23% respectively in Q1 2026, successfully offsetting the decline from Humira biosimilars. This strong performance prompted management to raise full-year adjusted EPS guidance to between $14.08 and $14.28, with a consensus price target of $265.50 above the current trading price. Conversely, Baxter faces significant headwinds including negative earnings, goodwill impairments, and operational overhangs such as shipment holds and tariff pressures. With a new CEO recently appointed and analyst targets below the current stock price, the article positions AbbVie as the clear winner for investors seeking stability, income, and growth, while labeling Baxter a speculative turnaround play.